Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 100% | 5860.38 | 577 / 578 | 89% | 104.42 | 1028 / 1155 |
breast | 68% | 1037.69 | 314 / 459 | 95% | 105.51 | 1066 / 1118 |
adrenal gland | 92% | 3277.91 | 238 / 258 | 45% | 24.34 | 103 / 230 |
brain | 49% | 1297.87 | 1299 / 2642 | 79% | 128.76 | 560 / 705 |
kidney | 42% | 594.39 | 37 / 89 | 85% | 129.18 | 762 / 901 |
bladder | 62% | 871.24 | 13 / 21 | 61% | 60.12 | 307 / 504 |
liver | 58% | 1099.32 | 131 / 226 | 50% | 30.44 | 203 / 406 |
pancreas | 20% | 209.80 | 65 / 328 | 83% | 76.41 | 148 / 178 |
thymus | 38% | 407.29 | 247 / 653 | 62% | 34.32 | 377 / 605 |
spleen | 100% | 19103.07 | 241 / 241 | 0% | 0 | 0 / 0 |
ovary | 26% | 289.02 | 46 / 180 | 73% | 49.58 | 312 / 430 |
uterus | 26% | 262.39 | 45 / 170 | 68% | 51.63 | 313 / 459 |
intestine | 36% | 516.82 | 345 / 966 | 54% | 39.80 | 284 / 527 |
stomach | 23% | 298.17 | 82 / 359 | 66% | 46.40 | 188 / 286 |
adipose | 83% | 2281.30 | 1004 / 1204 | 0% | 0 | 0 / 0 |
esophagus | 29% | 375.73 | 414 / 1445 | 54% | 29.82 | 99 / 183 |
peripheral blood | 81% | 12991.09 | 757 / 929 | 0% | 0 | 0 / 0 |
skin | 3% | 27.27 | 61 / 1809 | 78% | 95.39 | 367 / 472 |
prostate | 46% | 546.27 | 113 / 245 | 31% | 10.24 | 154 / 502 |
lymph node | 0% | 0 | 0 / 0 | 76% | 97.10 | 22 / 29 |
tonsil | 0% | 0 | 0 / 0 | 76% | 60.37 | 34 / 45 |
blood vessel | 75% | 2054.70 | 1001 / 1335 | 0% | 0 | 0 / 0 |
heart | 47% | 902.21 | 405 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 19% | 15.76 | 15 / 80 |
muscle | 2% | 19.18 | 19 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0042116 | Biological process | macrophage activation |
GO_0019722 | Biological process | calcium-mediated signaling |
GO_0032819 | Biological process | positive regulation of natural killer cell proliferation |
GO_0030101 | Biological process | natural killer cell activation |
GO_0042267 | Biological process | natural killer cell mediated cytotoxicity |
GO_0006955 | Biological process | immune response |
GO_0001788 | Biological process | antibody-dependent cellular cytotoxicity |
GO_0043491 | Biological process | phosphatidylinositol 3-kinase/protein kinase B signal transduction |
GO_0043320 | Biological process | natural killer cell degranulation |
GO_0032760 | Biological process | positive regulation of tumor necrosis factor production |
GO_0038094 | Biological process | Fc-gamma receptor signaling pathway |
GO_0007166 | Biological process | cell surface receptor signaling pathway |
GO_0005615 | Cellular component | extracellular space |
GO_0009897 | Cellular component | external side of plasma membrane |
GO_0005886 | Cellular component | plasma membrane |
GO_0033001 | Cellular component | Fc-gamma receptor III complex |
GO_0070062 | Cellular component | extracellular exosome |
GO_0019772 | Molecular function | low-affinity IgG receptor activity |
GO_0140375 | Molecular function | immune receptor activity |
GO_0019770 | Molecular function | IgG receptor activity |
GO_0019864 | Molecular function | IgG binding |
GO_0005515 | Molecular function | protein binding |
Gene name | FCGR3A |
Protein name | Fc gamma receptor IIIa CD16A Low affinity immunoglobulin gamma Fc region receptor III-A Fc of IgG low affinity IIIa receptor isoform 1 Low affinity immunoglobulin gamma Fc region receptor III-A (IgG Fc receptor III-A) (CD16-II) (CD16a antigen) (Fc-gamma RIII-alpha) (Fc-gamma RIII) (Fc-gamma RIIIa) (FcRIII) (FcRIIIa) (FcgammaRIIIA) (FcR-10) (IgG Fc receptor III-2) (CD antigen CD16a) |
Synonyms | IGFR3 CD16A FCGR3 FCG3 |
Description | FUNCTION: Receptor for the invariable Fc fragment of immunoglobulin gamma (IgG). Optimally activated upon binding of clustered antigen-IgG complexes displayed on cell surfaces, triggers lysis of antibody-coated cells, a process known as antibody-dependent cellular cytotoxicity (ADCC). Does not bind free monomeric IgG, thus avoiding inappropriate effector cell activation in the absence of antigenic trigger . Mediates IgG effector functions on natural killer (NK) cells. Binds antigen-IgG complexes generated upon infection and triggers NK cell-dependent cytokine production and degranulation to limit viral load and propagation. Involved in the generation of memory-like adaptive NK cells capable to produce high amounts of IFNG and to efficiently eliminate virus-infected cells via ADCC . Regulates NK cell survival and proliferation, in particular by preventing NK cell progenitor apoptosis . Fc-binding subunit that associates with CD247 and/or FCER1G adapters to form functional signaling complexes. Following the engagement of antigen-IgG complexes, triggers phosphorylation of immunoreceptor tyrosine-based activation motif (ITAM)-containing adapters with subsequent activation of phosphatidylinositol 3-kinase signaling and sustained elevation of intracellular calcium that ultimately drive NK cell activation. The ITAM-dependent signaling coupled to receptor phosphorylation by PKC mediates robust intracellular calcium flux that leads to production of pro-inflammatory cytokines, whereas in the absence of receptor phosphorylation it mainly activates phosphatidylinositol 3-kinase signaling leading to cell degranulation . Costimulates NK cells and trigger lysis of target cells independently of IgG binding . Mediates the antitumor activities of therapeutic antibodies. Upon ligation on monocytes triggers TNFA-dependent ADCC of IgG-coated tumor cells . Mediates enhanced ADCC in response to afucosylated IgGs . .; FUNCTION: (Microbial infection) Involved in Dengue virus pathogenesis via antibody-dependent enhancement (ADE) mechanism. Secondary infection with Dengue virus triggers elevated levels of afucosylated non-neutralizing IgG1s with reactivity to viral envelope/E protein. Viral antigen-IgG1 complexes bind with high affinity to FCGR3A, facilitating virus entry in myeloid cells and subsequent viral replication. . |
Accessions | ENST00000699493.1 A0A2H4Z8F3 A0A2H4Z8E5 P08637 ENST00000699395.1 ENST00000699400.1 A0A2H4Z8F0 ENST00000699401.1 ENST00000699397.1 ENST00000426740.8 A0A0S2Z3S7 ENST00000442336.2 A0A1W2PQB1 ENST00000699399.1 ENST00000436743.7 A0A2H4Z8E2 A0A2H4Z8F2 A0A8V8TNB3 A0A2H4Z8E3 A0A8V8TPL1 H0Y755 A0A8V8TNB8 C9JC71 ENST00000367967.8 ENST00000443193.6 ENST00000699396.1 ENST00000699398.1 A0A8V8TQ03 |